miR-192

miR-192 (microRNA-192) is a highly conserved, endogenous non-coding microRNA that plays a critical role in post-transcriptional gene regulation. It acts as a tumor suppressor in various cancers, including colorectal, breast, and lung cancers, by targeting key genes involved in cell cycle progression, proliferation, and apoptosis (such as DHFR, BCL2, and RB1). Conversely, in renal tissues, miR-192 upregulation by TGF-beta 1 has been implicated in the pathogenesis of diabetic nephropathy and renal fibrosis by targeting E-box repressors Zeb1/2 and promoting collagen accumulation. While miR-192 itself is not an approved therapeutic, synthetic miR-192 mimics and inhibitors (such as LNA-anti-miR-192) are widely utilized as research reagents to investigate gene regulation, oncogenesis, and fibrotic pathways. Curamir Therapeutics, in collaboration with Stony Brook University, is developing modified miRNA mimetics based on this platform for oncology indications.

Other names

hsa-miR-192hsa-miR192hsa-miR 192miR-192-5pmiR192-5pmiR 192-5pmicroRNA-192microRNA192microRNA 192